These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 11966500

  • 1. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride.
    Abitbol V, Mary JY, Roux C, Soulé JC, Belaiche J, Dupas JL, Gendre JP, Lerebours E, Chaussade S, Groupe D'etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Aliment Pharmacol Ther; 2002 May; 16(5):919-27. PubMed ID: 11966500
    [Abstract] [Full Text] [Related]

  • 2. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study.
    Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, Belin TR, Shanahan F.
    Aliment Pharmacol Ther; 1996 Oct; 10(5):777-86. PubMed ID: 8899087
    [Abstract] [Full Text] [Related]

  • 3. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
    Stokkers PC, Deley M, Van Der Spek M, Verberne HJ, Van Deventer SJ, Hommes DW.
    Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
    [Abstract] [Full Text] [Related]

  • 4. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease.
    von Tirpitz C, Klaus J, Brückel J, Rieber A, Scholer A, Adler G, Böhm BO, Reinshagen M.
    Eur J Gastroenterol Hepatol; 2000 Jan; 12(1):19-24. PubMed ID: 10656205
    [Abstract] [Full Text] [Related]

  • 5. Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticosteroids: a prospective, randomized, double-blind study.
    Lippuner K, Haller B, Casez JP, Montandon A, Jaeger P.
    Miner Electrolyte Metab; 1996 Jan; 22(4):207-13. PubMed ID: 8807623
    [Abstract] [Full Text] [Related]

  • 6. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
    Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Steinhart H, Greenberg G.
    Clin Gastroenterol Hepatol; 2005 Feb; 3(2):122-32. PubMed ID: 15704046
    [Abstract] [Full Text] [Related]

  • 7. Review article: Osteoporosis and inflammatory bowel disease.
    Bernstein CN, Leslie WD.
    Aliment Pharmacol Ther; 2004 May 01; 19(9):941-52. PubMed ID: 15113361
    [Abstract] [Full Text] [Related]

  • 8. Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease.
    Bernstein CN, Bector S, Leslie WD.
    Am J Gastroenterol; 2003 Nov 01; 98(11):2468-73. PubMed ID: 14638350
    [Abstract] [Full Text] [Related]

  • 9. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude CJ, Stokkers PC, Russel MG, Oldenburg B, Pierik M, Roos JC, van Hogezand RA, Dik VK, Oostlander AE, Netelenbos JC, van de Langerijt L, Hommes DW, Lips P, Dutch Initiative on Crohn and Colitis (ICC).
    Gut; 2014 Sep 01; 63(9):1424-30. PubMed ID: 24146170
    [Abstract] [Full Text] [Related]

  • 10. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
    Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P, Loeb G, Rouillon A, Barry S, Evreux JC, Avouac B, Marchandise X.
    Osteoporos Int; 1998 Sep 01; 8(1):4-12. PubMed ID: 9692071
    [Abstract] [Full Text] [Related]

  • 11. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T.
    Osteoporos Int; 2003 Sep 01; 14(9):741-9. PubMed ID: 12827224
    [Abstract] [Full Text] [Related]

  • 12. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial.
    Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T, Tanigawara Y, Hayashi Y, Fukunaga M, Shiraki M, Nakamura T.
    J Clin Endocrinol Metab; 2005 Sep 01; 90(9):5031-6. PubMed ID: 15972580
    [Abstract] [Full Text] [Related]

  • 13. Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements.
    Nagant de Deuxchaisnes C, Devogelaer JP, Depresseux G, Malghem J, Maldague B.
    J Bone Miner Res; 1990 Mar 01; 5 Suppl 1():S5-26. PubMed ID: 2187327
    [Abstract] [Full Text] [Related]

  • 14. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate.
    Ringe JD, Dorst A, Kipshoven C, Rovati LC, Setnikar I.
    Osteoporos Int; 1998 Mar 01; 8(1):47-52. PubMed ID: 9692077
    [Abstract] [Full Text] [Related]

  • 15. Monofluorophosphate increases lumbar bone density in osteopenic patients: a double-masked randomized study.
    Sebert JL, Richard P, Mennecier I, Bisset JP, Loeb G.
    Osteoporos Int; 1995 Mar 01; 5(2):108-14. PubMed ID: 7599447
    [Abstract] [Full Text] [Related]

  • 16. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound.
    Frediani B, Falsetti P, Baldi F, Acciai C, Filippou G, Marcolongo R.
    Bone; 2003 Oct 01; 33(4):575-81. PubMed ID: 14555261
    [Abstract] [Full Text] [Related]

  • 17. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study.
    Guaydier-Souquières G, Kotzki PO, Sabatier JP, Basse-Cathalinat B, Loeb G.
    Osteoporos Int; 1996 Oct 01; 6(2):171-7. PubMed ID: 8704358
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and harms of nasal calcitonin in improving bone density in young patients with inflammatory bowel disease: a randomized, placebo-controlled, double-blind trial.
    Pappa HM, Saslowsky TM, Filip-Dhima R, DiFabio D, Hassani Lahsinoui H, Akkad A, Grand RJ, Gordon CM.
    Am J Gastroenterol; 2011 Aug 01; 106(8):1527-43. PubMed ID: 21519359
    [Abstract] [Full Text] [Related]

  • 19. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease.
    Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP.
    Aliment Pharmacol Ther; 2003 Dec 01; 18(11-12):1121-7. PubMed ID: 14653832
    [Abstract] [Full Text] [Related]

  • 20. Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis.
    Rizzoli R, Chevalley T, Slosman DO, Bonjour JP.
    Osteoporos Int; 1995 Jan 01; 5(1):39-46. PubMed ID: 7703623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.